Navigation Links
Genetic variations may help identify best candidates for preventive breast cancer drugs
Date:6/13/2013

ROCHESTER, Minn. -- Newly discovered genetic variations may help predict breast cancer risk in women who receive preventive breast cancer therapy with the selective estrogen receptor modulator drugs tamoxifen and raloxifene, a Mayo Clinic-led study has found. The study is published in the journal Cancer Discovery.

"Our findings are important because we identified genetic factors that could eventually be used to select women who should be offered the drugs for prevention," said James Ingle, M.D., an oncologist at Mayo Clinic.

Dr. Ingle and collaborators at the National Surgical Adjuvant Breast and Bowel Project (NSABP) and the RIKEN Center for Genomic Medicine conducted a genome-wide association study involving 592 patients who developed breast cancer while receiving preventive therapy and 1,171 matched controls. Participants were selected from 33,000 women enrolled in the NSABP breast cancer prevention trials. This research was supported by a Pharmacogenomics Research Network grant from the National Institute of General Medical Science and the National Cancer Institute.

The researchers analyzed participants' DNA to identify variations in their genetic makeup and identified two genetic variations, or single nucleotide polymorphisms (SNPs), that were associated with breast cancer risk in or near the genes ZNF423 and CTSO.

They discovered that women with favorable variations in these genes were more likely to respond to preventive therapy with the drugs while women with unfavorable variations may not. In addition, women with unfavorable variations had a five-fold increased risk of developing breast cancer.

Dr. Ingle says the recent guidelines by the U.S. Preventive Services Task Force emphasize that selective estrogen receptor modulators (SERM) therapy with tamoxifen and raloxifene can lower a woman's risk for developing breast cancer. However, there currently is no way to know which women will benefit from
'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related medicine news :

1. IntegraGen launches ARISk test, a genetic screening tool for autism in high-risk children
2. 2 genetic deletions in human genome linked to the development of aggressive prostate cancer
3. Head, Body Lice Are Genetically Very Similar
4. Certain Genetic Regions May Be Tied to Osteoporosis
5. Study of half siblings provides genetic clues to autism
6. Genetic variants, tobacco exposure and lung cancer risk
7. Research Gets Closer to Genetic Roots of Glaucoma
8. Moffitt researcher awarded GE grant to develop tool to detect breast cancer metastasis genetic risks
9. Genetically modified T cell therapy shown to be safe, lasting in decade-long study of HIV patients
10. Some women may be genetically predisposed to smoking-related hot flashes
11. Genetic abnormalities in benign or malignant tissues predict relapse of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... 2014 AttorneyOne.com, a recognized authority on law, ... the FDA on Sit and Slim II . ... purchase or use Sit and Slim II because it contains ... promoted as weight loss product on various websites and possibly ... in 2010 for safety reasons, can significantly increase blood pressure ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... New York (PRWEB) October 19, 2014 ... Nations Population Fund, welcomes news of a ceasefire agreement ... the more than 200 girls who were kidnapped from ... girls have languished in captivity long enough, and it ... schools and communities," stated Dr. Osotimehin. , "We owe ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 SweetDressy.com, a ... recently announced its promotion for long evening dresses ... enjoy the special offer; the current discount is up ... of the industry pioneers in the fashion field. Its ... for ladies dwelling in various parts of the world. ...
Breaking Medicine News(10 mins):Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2
... Zephyr(R) EBV Technology Enables Pulmonx to Develop Both ... ALTO, Calif., May 13 Pulmonx, a medical ... with emphysema, announced today that it has acquired ... its endobronchial valve (EBV) technology platform and associated ...
... Technologies Limited (ASX: TEO), a global healthcare company, ... catheter it is developing with Vascular Pathways, Inc., ... Award. , "Telesso is pleased to receive another ... may revolutionize peripheral IV placement," said Telesso,s CEO ...
... Zimmer Holdings, Inc. (NYSE: ZMH ; SWX: ... Bank 34th Annual Health Care Conference in Boston, Massachusetts, on ... of the presentation can be accessed via Zimmer,s Investor Relations ... The webcast will be archived for replay following the conference. ...
... that it has enrolled its 1,000th patient into its ... esponsiveness with A V erifyNow(R) Assay I ... S afety). The trial is specifically designed to demonstrate ... patients who are poor responders to clopidogrel (Plavix(R)). The ...
... ESRX ) announced that it will present at ... 19, 2009 at 10:10 a.m. EDT at the InterContinental Hotel ... Internet and can be accessed on the investor relations section ... RealPlayer or Windows Media Player is needed to listen to ...
... reduced in rodent models of liver injury, leading ... two factors that contribute to endothelial dysfunction and ... the analysis of the human Cystathionase gene promoter ... Administration of an FXR ligand to carbon tetrachloride ...
Cached Medicine News:Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 2Health News:Pulmonx Acquires Assets of Emphasys Medical and Unveils Combined Product Portfolio at International Conference of the American Thoracic Society (ATS) Annual Meeting 3Health News:Accumetrics, Inc. Announces 1000th Patient Enrolled in GRAVITAS Trial 2Health News:Farnesoid X receptor regulates cystathionase 2
(Date:10/17/2014)... 2014 The following is being released ... The Green Park Collaborative (GPC) will bring ... payers, medical device and pharmaceutical companies, as well ... 12, 2015 at its first ever workshop on ... treatments.  Participants will discuss study designs to evaluate ...
(Date:10/17/2014)...  UBM Medica US announces that Endocrinology Network ... clinicians who treat patients with type 2 diabetes ... of insulin .  Nearly all patients ... – daily injections of one or more insulin ... function of pancreatic beta cells. Insulin is a very ...
(Date:10/17/2014)... -- Ameritox SM , the nation,s leader in medication monitoring ... , M.D., as Chief Medical Officer. In this role, ... for healthcare providers, patients and managed care plans.   ... variety of healthcare companies that have provided him with ... health sides of Ameritox,s business. He most recently served ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2
... Visica 2(TM) Treatment System Selected as Exclusive Cryoablation ... ... The American College of,Surgeons Oncology Group (ACOSOG) which just ... Phase II Trial Exploring,the Success of Cryoablation Therapy in the ...
... results to be presented at 2008 ICAAC/IDSA ... Sequella, Inc., a,clinical-stage biopharmaceutical company focused ... epidemic potential, announces the,successful demonstration of synergistic ... resulting from in vitro combination,studies of Sequella ...
Cached Medicine Technology:NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 2NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation 3Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207 2
...
...
...
Conforms to the convexity of the lens providing easier access to anterior capsule. Reduces pontential of corneal touch. 35G x 5/8in (.50 x 16mm)...
Medicine Products: